Fig. 4: cART + 3HP increases Mtb-specific TH1/TH17 response in pulmonary compartment of Mtb/SIV co-infected RMs.
Percentage of CD4+IFNγ+ T cells in response to A ESAT-6/CFP-10, B Mtb CW, CD4+TNFα+ T cells in response to C ESAT-6/CFP-10, D Mtb CW and CD4+IL-17+ T cells in response to E ESAT-6/CFP-10, and F Mtb CW were measured in BAL at weeks 5, 11 and necropsy in Mtb/SIV co-infected RMs treated with cART (n = 4) or cART+3HP (n = 6). Data are presented as mean ± SEM. Percentage of CD4+ T cells expressing either IFNγ, TNFα or IL17 was measured in lung at necropsy in response to G ESAT = 6/CFP-10 and H Mtb CW in cART (n = 4) or cART+3HP (n = 6). Significance was determined using one-way ANOVA with Sidak’s or Tukey’s correction as applicable. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are presented as mean ± SEM. I Levels of cytokines were measured in BAL supernatant of cART+3HP-treated RMs (n = 6) at necropsy using NHP XL Cytokine Luminex Performance Premixed Kit. The data were analyzed using Belysa software. Significance was determined using Mann–Whitney two-tailed Student’s t test to determine significance between two groups. P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are presented as mean ± SEM. J QAIGEN ingenuity pathway analysis was performed on fastq files of the cDNA library generated from cART and cART+3HP-treated RM lung tissues at necropsy. Based on the input data, IPA analyzed and identified the significantly impacted pathways. Source data are provided as a Source Data file.
